nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Epirubicin—liver cancer	0.311	0.519	CiPCiCtD
Topotecan—Topoisomerase Inhibitors—Doxorubicin—liver cancer	0.288	0.481	CiPCiCtD
Topotecan—lung cancer—liver cancer	0.278	1	CtDrD
Topotecan—ABCG2—Sorafenib—liver cancer	0.0277	0.395	CbGbCtD
Topotecan—ABCG2—Doxorubicin—liver cancer	0.0168	0.24	CbGbCtD
Topotecan—ABCB1—Sorafenib—liver cancer	0.00999	0.142	CbGbCtD
Topotecan—ABCB1—Doxorubicin—liver cancer	0.00606	0.0864	CbGbCtD
Topotecan—CYP3A4—Sorafenib—liver cancer	0.00599	0.0853	CbGbCtD
Topotecan—Hepatic pain—Sorafenib—liver cancer	0.00489	0.125	CcSEcCtD
Topotecan—Tumour pain—Sorafenib—liver cancer	0.00432	0.11	CcSEcCtD
Topotecan—CYP3A4—Doxorubicin—liver cancer	0.00363	0.0517	CbGbCtD
Topotecan—Metastatic neoplasm—Epirubicin—liver cancer	0.000786	0.0201	CcSEcCtD
Topotecan—Mucosal inflammation—Sorafenib—liver cancer	0.000736	0.0188	CcSEcCtD
Topotecan—Metastatic neoplasm—Doxorubicin—liver cancer	0.000727	0.0186	CcSEcCtD
Topotecan—Interstitial lung disease—Sorafenib—liver cancer	0.000576	0.0147	CcSEcCtD
Topotecan—Pleural effusion—Sorafenib—liver cancer	0.000532	0.0136	CcSEcCtD
Topotecan—Acute leukaemia—Epirubicin—liver cancer	0.000527	0.0135	CcSEcCtD
Topotecan—Acute leukaemia—Doxorubicin—liver cancer	0.000488	0.0125	CcSEcCtD
Topotecan—Blood bilirubin increased—Sorafenib—liver cancer	0.000431	0.011	CcSEcCtD
Topotecan—Neuropathy—Sorafenib—liver cancer	0.000383	0.00978	CcSEcCtD
Topotecan—Bullous eruption—Epirubicin—liver cancer	0.000381	0.00974	CcSEcCtD
Topotecan—Neoplasm—Sorafenib—liver cancer	0.000369	0.00941	CcSEcCtD
Topotecan—Bullous eruption—Doxorubicin—liver cancer	0.000353	0.00901	CcSEcCtD
Topotecan—Myelosuppression—Epirubicin—liver cancer	0.000321	0.00821	CcSEcCtD
Topotecan—Myelosuppression—Doxorubicin—liver cancer	0.000297	0.00759	CcSEcCtD
Topotecan—Irinotecan—ALB—liver cancer	0.000283	1	CrCbGaD
Topotecan—Mucosal inflammation—Epirubicin—liver cancer	0.000272	0.00695	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000266	0.00681	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000261	0.00667	CcSEcCtD
Topotecan—Mucosal inflammation—Doxorubicin—liver cancer	0.000252	0.00643	CcSEcCtD
Topotecan—Febrile neutropenia—Epirubicin—liver cancer	0.00025	0.0064	CcSEcCtD
Topotecan—Pelvic pain—Epirubicin—liver cancer	0.000248	0.00633	CcSEcCtD
Topotecan—Neutropenia—Sorafenib—liver cancer	0.000239	0.00611	CcSEcCtD
Topotecan—Febrile neutropenia—Doxorubicin—liver cancer	0.000232	0.00592	CcSEcCtD
Topotecan—Pneumonia—Sorafenib—liver cancer	0.000229	0.00586	CcSEcCtD
Topotecan—Pelvic pain—Doxorubicin—liver cancer	0.000229	0.00585	CcSEcCtD
Topotecan—Infestation NOS—Sorafenib—liver cancer	0.000228	0.00582	CcSEcCtD
Topotecan—Infestation—Sorafenib—liver cancer	0.000228	0.00582	CcSEcCtD
Topotecan—Neuropathy peripheral—Sorafenib—liver cancer	0.000224	0.00571	CcSEcCtD
Topotecan—Stomatitis—Sorafenib—liver cancer	0.000222	0.00568	CcSEcCtD
Topotecan—Neuralgia—Epirubicin—liver cancer	0.000217	0.00554	CcSEcCtD
Topotecan—Hepatobiliary disease—Sorafenib—liver cancer	0.000216	0.00551	CcSEcCtD
Topotecan—Epistaxis—Sorafenib—liver cancer	0.000215	0.00549	CcSEcCtD
Topotecan—Lung disorder—Epirubicin—liver cancer	0.000213	0.00544	CcSEcCtD
Topotecan—Haemoglobin—Sorafenib—liver cancer	0.000206	0.00526	CcSEcCtD
Topotecan—Haemorrhage—Sorafenib—liver cancer	0.000205	0.00523	CcSEcCtD
Topotecan—Neuralgia—Doxorubicin—liver cancer	0.000201	0.00512	CcSEcCtD
Topotecan—Lung disorder—Doxorubicin—liver cancer	0.000197	0.00503	CcSEcCtD
Topotecan—Rash erythematous—Epirubicin—liver cancer	0.000197	0.00502	CcSEcCtD
Topotecan—Pleural effusion—Epirubicin—liver cancer	0.000197	0.00502	CcSEcCtD
Topotecan—Angiopathy—Sorafenib—liver cancer	0.000186	0.00474	CcSEcCtD
Topotecan—Immune system disorder—Sorafenib—liver cancer	0.000185	0.00472	CcSEcCtD
Topotecan—Rigors—Epirubicin—liver cancer	0.000185	0.00471	CcSEcCtD
Topotecan—Mediastinal disorder—Sorafenib—liver cancer	0.000184	0.00471	CcSEcCtD
Topotecan—Pleural effusion—Doxorubicin—liver cancer	0.000182	0.00465	CcSEcCtD
Topotecan—Rash erythematous—Doxorubicin—liver cancer	0.000182	0.00465	CcSEcCtD
Topotecan—Alopecia—Sorafenib—liver cancer	0.000181	0.00462	CcSEcCtD
Topotecan—Malnutrition—Sorafenib—liver cancer	0.000178	0.00455	CcSEcCtD
Topotecan—Extravasation—Epirubicin—liver cancer	0.000173	0.00441	CcSEcCtD
Topotecan—Muscle spasms—Sorafenib—liver cancer	0.000171	0.00438	CcSEcCtD
Topotecan—Rigors—Doxorubicin—liver cancer	0.000171	0.00436	CcSEcCtD
Topotecan—Hyperbilirubinaemia—Epirubicin—liver cancer	0.000166	0.00423	CcSEcCtD
Topotecan—Anaemia—Sorafenib—liver cancer	0.000165	0.00421	CcSEcCtD
Topotecan—Angioedema—Sorafenib—liver cancer	0.000163	0.00416	CcSEcCtD
Topotecan—Extravasation—Doxorubicin—liver cancer	0.00016	0.00408	CcSEcCtD
Topotecan—Leukopenia—Sorafenib—liver cancer	0.000159	0.00407	CcSEcCtD
Topotecan—Blood bilirubin increased—Epirubicin—liver cancer	0.000159	0.00407	CcSEcCtD
Topotecan—Bone pain—Epirubicin—liver cancer	0.000157	0.00402	CcSEcCtD
Topotecan—Cough—Sorafenib—liver cancer	0.000155	0.00397	CcSEcCtD
Topotecan—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000153	0.00392	CcSEcCtD
Topotecan—Myalgia—Sorafenib—liver cancer	0.000152	0.00388	CcSEcCtD
Topotecan—Arthralgia—Sorafenib—liver cancer	0.000152	0.00388	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000151	0.00385	CcSEcCtD
Topotecan—Pulmonary embolism—Epirubicin—liver cancer	0.000151	0.00385	CcSEcCtD
Topotecan—Blood bilirubin increased—Doxorubicin—liver cancer	0.000147	0.00376	CcSEcCtD
Topotecan—Bone pain—Doxorubicin—liver cancer	0.000145	0.00372	CcSEcCtD
Topotecan—Anaphylactic shock—Sorafenib—liver cancer	0.000145	0.00371	CcSEcCtD
Topotecan—Colitis—Epirubicin—liver cancer	0.000145	0.00369	CcSEcCtD
Topotecan—Infection—Sorafenib—liver cancer	0.000144	0.00369	CcSEcCtD
Topotecan—Nervous system disorder—Sorafenib—liver cancer	0.000143	0.00364	CcSEcCtD
Topotecan—Thrombocytopenia—Sorafenib—liver cancer	0.000142	0.00364	CcSEcCtD
Topotecan—Neuropathy—Epirubicin—liver cancer	0.000141	0.00361	CcSEcCtD
Topotecan—Skin disorder—Sorafenib—liver cancer	0.000141	0.00361	CcSEcCtD
Topotecan—Pulmonary embolism—Doxorubicin—liver cancer	0.000139	0.00356	CcSEcCtD
Topotecan—Anorexia—Sorafenib—liver cancer	0.000139	0.00354	CcSEcCtD
Topotecan—Rash maculo-papular—Epirubicin—liver cancer	0.000137	0.0035	CcSEcCtD
Topotecan—Neoplasm—Epirubicin—liver cancer	0.000136	0.00348	CcSEcCtD
Topotecan—Colitis—Doxorubicin—liver cancer	0.000134	0.00342	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000132	0.00338	CcSEcCtD
Topotecan—Neuropathy—Doxorubicin—liver cancer	0.000131	0.00334	CcSEcCtD
Topotecan—Sepsis—Epirubicin—liver cancer	0.000131	0.00334	CcSEcCtD
Topotecan—Dyspnoea—Sorafenib—liver cancer	0.00013	0.00331	CcSEcCtD
Topotecan—Dyspepsia—Sorafenib—liver cancer	0.000128	0.00327	CcSEcCtD
Topotecan—Rash maculo-papular—Doxorubicin—liver cancer	0.000127	0.00324	CcSEcCtD
Topotecan—Decreased appetite—Sorafenib—liver cancer	0.000126	0.00323	CcSEcCtD
Topotecan—Neoplasm—Doxorubicin—liver cancer	0.000126	0.00322	CcSEcCtD
Topotecan—Gastrointestinal disorder—Sorafenib—liver cancer	0.000126	0.00321	CcSEcCtD
Topotecan—Fatigue—Sorafenib—liver cancer	0.000125	0.0032	CcSEcCtD
Topotecan—Constipation—Sorafenib—liver cancer	0.000124	0.00318	CcSEcCtD
Topotecan—Pain—Sorafenib—liver cancer	0.000124	0.00318	CcSEcCtD
Topotecan—Sepsis—Doxorubicin—liver cancer	0.000121	0.00309	CcSEcCtD
Topotecan—Gastrointestinal pain—Sorafenib—liver cancer	0.000119	0.00304	CcSEcCtD
Topotecan—Urticaria—Sorafenib—liver cancer	0.000116	0.00295	CcSEcCtD
Topotecan—Body temperature increased—Sorafenib—liver cancer	0.000115	0.00294	CcSEcCtD
Topotecan—Abdominal pain—Sorafenib—liver cancer	0.000115	0.00294	CcSEcCtD
Topotecan—Dermatitis bullous—Epirubicin—liver cancer	0.000114	0.00292	CcSEcCtD
Topotecan—Anaphylactoid reaction—Epirubicin—liver cancer	0.000113	0.00289	CcSEcCtD
Topotecan—Lethargy—Epirubicin—liver cancer	0.000112	0.00285	CcSEcCtD
Topotecan—Hypersensitivity—Sorafenib—liver cancer	0.000107	0.00274	CcSEcCtD
Topotecan—Dermatitis bullous—Doxorubicin—liver cancer	0.000106	0.0027	CcSEcCtD
Topotecan—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000105	0.00267	CcSEcCtD
Topotecan—Asthenia—Sorafenib—liver cancer	0.000104	0.00267	CcSEcCtD
Topotecan—Cardiac arrest—Epirubicin—liver cancer	0.000104	0.00266	CcSEcCtD
Topotecan—Lethargy—Doxorubicin—liver cancer	0.000103	0.00264	CcSEcCtD
Topotecan—Pruritus—Sorafenib—liver cancer	0.000103	0.00263	CcSEcCtD
Topotecan—Diarrhoea—Sorafenib—liver cancer	9.95e-05	0.00254	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Epirubicin—liver cancer	9.85e-05	0.00252	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Epirubicin—liver cancer	9.64e-05	0.00246	CcSEcCtD
Topotecan—Cardiac arrest—Doxorubicin—liver cancer	9.62e-05	0.00246	CcSEcCtD
Topotecan—Dizziness—Sorafenib—liver cancer	9.62e-05	0.00246	CcSEcCtD
Topotecan—Vomiting—Sorafenib—liver cancer	9.25e-05	0.00236	CcSEcCtD
Topotecan—Rash—Sorafenib—liver cancer	9.17e-05	0.00234	CcSEcCtD
Topotecan—Dermatitis—Sorafenib—liver cancer	9.16e-05	0.00234	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Doxorubicin—liver cancer	9.11e-05	0.00233	CcSEcCtD
Topotecan—Headache—Sorafenib—liver cancer	9.11e-05	0.00233	CcSEcCtD
Topotecan—Pancytopenia—Epirubicin—liver cancer	8.98e-05	0.00229	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Doxorubicin—liver cancer	8.92e-05	0.00228	CcSEcCtD
Topotecan—Neutropenia—Epirubicin—liver cancer	8.84e-05	0.00226	CcSEcCtD
Topotecan—Nausea—Sorafenib—liver cancer	8.64e-05	0.00221	CcSEcCtD
Topotecan—Weight increased—Epirubicin—liver cancer	8.6e-05	0.0022	CcSEcCtD
Topotecan—Pneumonia—Epirubicin—liver cancer	8.48e-05	0.00217	CcSEcCtD
Topotecan—Infestation—Epirubicin—liver cancer	8.43e-05	0.00215	CcSEcCtD
Topotecan—Infestation NOS—Epirubicin—liver cancer	8.43e-05	0.00215	CcSEcCtD
Topotecan—Pancytopenia—Doxorubicin—liver cancer	8.3e-05	0.00212	CcSEcCtD
Topotecan—Neuropathy peripheral—Epirubicin—liver cancer	8.26e-05	0.00211	CcSEcCtD
Topotecan—Stomatitis—Epirubicin—liver cancer	8.21e-05	0.0021	CcSEcCtD
Topotecan—Neutropenia—Doxorubicin—liver cancer	8.18e-05	0.00209	CcSEcCtD
Topotecan—Sweating—Epirubicin—liver cancer	8.08e-05	0.00206	CcSEcCtD
Topotecan—Hepatobiliary disease—Epirubicin—liver cancer	7.97e-05	0.00204	CcSEcCtD
Topotecan—Weight increased—Doxorubicin—liver cancer	7.96e-05	0.00203	CcSEcCtD
Topotecan—Epistaxis—Epirubicin—liver cancer	7.95e-05	0.00203	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—KDR—liver cancer	7.86e-05	0.00554	CbGpPWpGaD
Topotecan—Pneumonia—Doxorubicin—liver cancer	7.84e-05	0.002	CcSEcCtD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	7.83e-05	0.00552	CbGpPWpGaD
Topotecan—Infestation NOS—Doxorubicin—liver cancer	7.8e-05	0.00199	CcSEcCtD
Topotecan—Infestation—Doxorubicin—liver cancer	7.8e-05	0.00199	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—liver cancer	7.74e-05	0.00545	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	7.73e-05	0.00545	CbGpPWpGaD
Topotecan—Neuropathy peripheral—Doxorubicin—liver cancer	7.64e-05	0.00195	CcSEcCtD
Topotecan—Haemoglobin—Epirubicin—liver cancer	7.6e-05	0.00194	CcSEcCtD
Topotecan—Stomatitis—Doxorubicin—liver cancer	7.6e-05	0.00194	CcSEcCtD
Topotecan—Rhinitis—Epirubicin—liver cancer	7.58e-05	0.00194	CcSEcCtD
Topotecan—Haemorrhage—Epirubicin—liver cancer	7.56e-05	0.00193	CcSEcCtD
Topotecan—Hypoaesthesia—Epirubicin—liver cancer	7.53e-05	0.00192	CcSEcCtD
Topotecan—Pharyngitis—Epirubicin—liver cancer	7.51e-05	0.00192	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	7.51e-05	0.00529	CbGpPWpGaD
Topotecan—Sweating—Doxorubicin—liver cancer	7.47e-05	0.00191	CcSEcCtD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—NDRG1—liver cancer	7.38e-05	0.0052	CbGpPWpGaD
Topotecan—Hepatobiliary disease—Doxorubicin—liver cancer	7.37e-05	0.00188	CcSEcCtD
Topotecan—Epistaxis—Doxorubicin—liver cancer	7.35e-05	0.00188	CcSEcCtD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	7.23e-05	0.0051	CbGpPWpGaD
Topotecan—Haemoglobin—Doxorubicin—liver cancer	7.03e-05	0.0018	CcSEcCtD
Topotecan—Rhinitis—Doxorubicin—liver cancer	7.02e-05	0.00179	CcSEcCtD
Topotecan—Haemorrhage—Doxorubicin—liver cancer	7e-05	0.00179	CcSEcCtD
Topotecan—Hypoaesthesia—Doxorubicin—liver cancer	6.96e-05	0.00178	CcSEcCtD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	6.95e-05	0.0049	CbGpPWpGaD
Topotecan—Pharyngitis—Doxorubicin—liver cancer	6.95e-05	0.00177	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	6.88e-05	0.00485	CbGpPWpGaD
Topotecan—Angiopathy—Epirubicin—liver cancer	6.86e-05	0.00175	CcSEcCtD
Topotecan—Immune system disorder—Epirubicin—liver cancer	6.83e-05	0.00175	CcSEcCtD
Topotecan—Mediastinal disorder—Epirubicin—liver cancer	6.82e-05	0.00174	CcSEcCtD
Topotecan—Chills—Epirubicin—liver cancer	6.79e-05	0.00173	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	6.74e-05	0.00475	CbGpPWpGaD
Topotecan—Alopecia—Epirubicin—liver cancer	6.68e-05	0.00171	CcSEcCtD
Topotecan—Malnutrition—Epirubicin—liver cancer	6.59e-05	0.00168	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	6.56e-05	0.00462	CbGpPWpGaD
Topotecan—CYP3A4—Xenobiotics—CYP2E1—liver cancer	6.55e-05	0.00462	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	6.55e-05	0.00461	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	6.5e-05	0.00458	CbGpPWpGaD
Topotecan—Back pain—Epirubicin—liver cancer	6.37e-05	0.00163	CcSEcCtD
Topotecan—Angiopathy—Doxorubicin—liver cancer	6.35e-05	0.00162	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	6.35e-05	0.00447	CbGpPWpGaD
Topotecan—Muscle spasms—Epirubicin—liver cancer	6.33e-05	0.00162	CcSEcCtD
Topotecan—Immune system disorder—Doxorubicin—liver cancer	6.32e-05	0.00161	CcSEcCtD
Topotecan—Mediastinal disorder—Doxorubicin—liver cancer	6.31e-05	0.00161	CcSEcCtD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	6.3e-05	0.00444	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—SERPINE1—liver cancer	6.29e-05	0.00444	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—JUN—liver cancer	6.29e-05	0.00443	CbGpPWpGaD
Topotecan—Chills—Doxorubicin—liver cancer	6.28e-05	0.0016	CcSEcCtD
Topotecan—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	6.27e-05	0.00442	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	6.2e-05	0.00437	CbGpPWpGaD
Topotecan—Alopecia—Doxorubicin—liver cancer	6.19e-05	0.00158	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—HMOX1—liver cancer	6.15e-05	0.00434	CbGpPWpGaD
Topotecan—Ill-defined disorder—Epirubicin—liver cancer	6.11e-05	0.00156	CcSEcCtD
Topotecan—Malnutrition—Doxorubicin—liver cancer	6.09e-05	0.00156	CcSEcCtD
Topotecan—Anaemia—Epirubicin—liver cancer	6.09e-05	0.00155	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—MAPK8—liver cancer	5.95e-05	0.00419	CbGpPWpGaD
Topotecan—Malaise—Epirubicin—liver cancer	5.94e-05	0.00152	CcSEcCtD
Topotecan—Leukopenia—Epirubicin—liver cancer	5.89e-05	0.00151	CcSEcCtD
Topotecan—Back pain—Doxorubicin—liver cancer	5.89e-05	0.00151	CcSEcCtD
Topotecan—Muscle spasms—Doxorubicin—liver cancer	5.86e-05	0.0015	CcSEcCtD
Topotecan—ABCB1—Allograft Rejection—IL12A—liver cancer	5.85e-05	0.00412	CbGpPWpGaD
Topotecan—Cough—Epirubicin—liver cancer	5.75e-05	0.00147	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	5.72e-05	0.00403	CbGpPWpGaD
Topotecan—Ill-defined disorder—Doxorubicin—liver cancer	5.65e-05	0.00144	CcSEcCtD
Topotecan—Anaemia—Doxorubicin—liver cancer	5.63e-05	0.00144	CcSEcCtD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	5.63e-05	0.00396	CbGpPWpGaD
Topotecan—Myalgia—Epirubicin—liver cancer	5.61e-05	0.00143	CcSEcCtD
Topotecan—Arthralgia—Epirubicin—liver cancer	5.61e-05	0.00143	CcSEcCtD
Topotecan—Chest pain—Epirubicin—liver cancer	5.61e-05	0.00143	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	5.57e-05	0.00142	CcSEcCtD
Topotecan—Discomfort—Epirubicin—liver cancer	5.54e-05	0.00141	CcSEcCtD
Topotecan—Malaise—Doxorubicin—liver cancer	5.49e-05	0.0014	CcSEcCtD
Topotecan—Leukopenia—Doxorubicin—liver cancer	5.45e-05	0.00139	CcSEcCtD
Topotecan—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	5.4e-05	0.00381	CbGpPWpGaD
Topotecan—Anaphylactic shock—Epirubicin—liver cancer	5.37e-05	0.00137	CcSEcCtD
Topotecan—Infection—Epirubicin—liver cancer	5.34e-05	0.00136	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC9C1—liver cancer	5.32e-05	0.00375	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—MYO5B—liver cancer	5.32e-05	0.00375	CbGpPWpGaD
Topotecan—Cough—Doxorubicin—liver cancer	5.32e-05	0.00136	CcSEcCtD
Topotecan—Nervous system disorder—Epirubicin—liver cancer	5.27e-05	0.00135	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	5.26e-05	0.00371	CbGpPWpGaD
Topotecan—Thrombocytopenia—Epirubicin—liver cancer	5.26e-05	0.00134	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	5.25e-05	0.0037	CbGpPWpGaD
Topotecan—Skin disorder—Epirubicin—liver cancer	5.22e-05	0.00133	CcSEcCtD
Topotecan—Hyperhidrosis—Epirubicin—liver cancer	5.2e-05	0.00133	CcSEcCtD
Topotecan—Arthralgia—Doxorubicin—liver cancer	5.19e-05	0.00133	CcSEcCtD
Topotecan—Myalgia—Doxorubicin—liver cancer	5.19e-05	0.00133	CcSEcCtD
Topotecan—Chest pain—Doxorubicin—liver cancer	5.19e-05	0.00133	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.15e-05	0.00132	CcSEcCtD
Topotecan—Discomfort—Doxorubicin—liver cancer	5.13e-05	0.00131	CcSEcCtD
Topotecan—Anorexia—Epirubicin—liver cancer	5.12e-05	0.00131	CcSEcCtD
Topotecan—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	5.12e-05	0.00361	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HNF4A—liver cancer	5.12e-05	0.00361	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—TERT—liver cancer	5.05e-05	0.00356	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	4.99e-05	0.00352	CbGpPWpGaD
Topotecan—Anaphylactic shock—Doxorubicin—liver cancer	4.97e-05	0.00127	CcSEcCtD
Topotecan—Infection—Doxorubicin—liver cancer	4.94e-05	0.00126	CcSEcCtD
Topotecan—CYP3A4—Irinotecan Pathway—APC—liver cancer	4.9e-05	0.00346	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	4.9e-05	0.00345	CbGpPWpGaD
Topotecan—Musculoskeletal discomfort—Epirubicin—liver cancer	4.9e-05	0.00125	CcSEcCtD
Topotecan—Nervous system disorder—Doxorubicin—liver cancer	4.88e-05	0.00125	CcSEcCtD
Topotecan—Thrombocytopenia—Doxorubicin—liver cancer	4.87e-05	0.00124	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	4.86e-05	0.00343	CbGpPWpGaD
Topotecan—Skin disorder—Doxorubicin—liver cancer	4.83e-05	0.00123	CcSEcCtD
Topotecan—Paraesthesia—Epirubicin—liver cancer	4.83e-05	0.00123	CcSEcCtD
Topotecan—Hyperhidrosis—Doxorubicin—liver cancer	4.81e-05	0.00123	CcSEcCtD
Topotecan—Dyspnoea—Epirubicin—liver cancer	4.79e-05	0.00122	CcSEcCtD
Topotecan—Anorexia—Doxorubicin—liver cancer	4.74e-05	0.00121	CcSEcCtD
Topotecan—Dyspepsia—Epirubicin—liver cancer	4.73e-05	0.00121	CcSEcCtD
Topotecan—CYP3A4—Xenobiotics—CYP1A1—liver cancer	4.71e-05	0.00332	CbGpPWpGaD
Topotecan—Decreased appetite—Epirubicin—liver cancer	4.67e-05	0.00119	CcSEcCtD
Topotecan—Gastrointestinal disorder—Epirubicin—liver cancer	4.64e-05	0.00119	CcSEcCtD
Topotecan—Fatigue—Epirubicin—liver cancer	4.63e-05	0.00118	CcSEcCtD
Topotecan—Constipation—Epirubicin—liver cancer	4.6e-05	0.00117	CcSEcCtD
Topotecan—Pain—Epirubicin—liver cancer	4.6e-05	0.00117	CcSEcCtD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	4.57e-05	0.00322	CbGpPWpGaD
Topotecan—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.53e-05	0.00116	CcSEcCtD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	4.53e-05	0.00319	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.47e-05	0.00315	CbGpPWpGaD
Topotecan—Paraesthesia—Doxorubicin—liver cancer	4.47e-05	0.00114	CcSEcCtD
Topotecan—Dyspnoea—Doxorubicin—liver cancer	4.43e-05	0.00113	CcSEcCtD
Topotecan—Feeling abnormal—Epirubicin—liver cancer	4.43e-05	0.00113	CcSEcCtD
Topotecan—Gastrointestinal pain—Epirubicin—liver cancer	4.39e-05	0.00112	CcSEcCtD
Topotecan—Dyspepsia—Doxorubicin—liver cancer	4.38e-05	0.00112	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—VEGFA—liver cancer	4.33e-05	0.00305	CbGpPWpGaD
Topotecan—Decreased appetite—Doxorubicin—liver cancer	4.32e-05	0.0011	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	4.32e-05	0.00305	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Doxorubicin—liver cancer	4.29e-05	0.0011	CcSEcCtD
Topotecan—Fatigue—Doxorubicin—liver cancer	4.29e-05	0.0011	CcSEcCtD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	4.28e-05	0.00302	CbGpPWpGaD
Topotecan—Urticaria—Epirubicin—liver cancer	4.27e-05	0.00109	CcSEcCtD
Topotecan—Constipation—Doxorubicin—liver cancer	4.25e-05	0.00109	CcSEcCtD
Topotecan—Pain—Doxorubicin—liver cancer	4.25e-05	0.00109	CcSEcCtD
Topotecan—Body temperature increased—Epirubicin—liver cancer	4.25e-05	0.00109	CcSEcCtD
Topotecan—Abdominal pain—Epirubicin—liver cancer	4.25e-05	0.00109	CcSEcCtD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—liver cancer	4.18e-05	0.00295	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—TP53—liver cancer	4.15e-05	0.00292	CbGpPWpGaD
Topotecan—Feeling abnormal—Doxorubicin—liver cancer	4.1e-05	0.00105	CcSEcCtD
Topotecan—Gastrointestinal pain—Doxorubicin—liver cancer	4.07e-05	0.00104	CcSEcCtD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	4.05e-05	0.00285	CbGpPWpGaD
Topotecan—Hypersensitivity—Epirubicin—liver cancer	3.96e-05	0.00101	CcSEcCtD
Topotecan—Urticaria—Doxorubicin—liver cancer	3.95e-05	0.00101	CcSEcCtD
Topotecan—Abdominal pain—Doxorubicin—liver cancer	3.93e-05	0.001	CcSEcCtD
Topotecan—Body temperature increased—Doxorubicin—liver cancer	3.93e-05	0.001	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	3.89e-05	0.00274	CbGpPWpGaD
Topotecan—Asthenia—Epirubicin—liver cancer	3.86e-05	0.000985	CcSEcCtD
Topotecan—Pruritus—Epirubicin—liver cancer	3.8e-05	0.000971	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—IL6—liver cancer	3.8e-05	0.00268	CbGpPWpGaD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	3.78e-05	0.00266	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	3.7e-05	0.00261	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—UGDH—liver cancer	3.68e-05	0.00259	CbGpPWpGaD
Topotecan—Diarrhoea—Epirubicin—liver cancer	3.68e-05	0.000939	CcSEcCtD
Topotecan—ABCB1—Allograft Rejection—IL12B—liver cancer	3.67e-05	0.00259	CbGpPWpGaD
Topotecan—Hypersensitivity—Doxorubicin—liver cancer	3.66e-05	0.000936	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.65e-05	0.00257	CbGpPWpGaD
Topotecan—Asthenia—Doxorubicin—liver cancer	3.57e-05	0.000911	CcSEcCtD
Topotecan—Dizziness—Epirubicin—liver cancer	3.55e-05	0.000908	CcSEcCtD
Topotecan—Pruritus—Doxorubicin—liver cancer	3.52e-05	0.000899	CcSEcCtD
Topotecan—Vomiting—Epirubicin—liver cancer	3.42e-05	0.000873	CcSEcCtD
Topotecan—Diarrhoea—Doxorubicin—liver cancer	3.4e-05	0.000869	CcSEcCtD
Topotecan—Rash—Epirubicin—liver cancer	3.39e-05	0.000866	CcSEcCtD
Topotecan—Dermatitis—Epirubicin—liver cancer	3.39e-05	0.000865	CcSEcCtD
Topotecan—Headache—Epirubicin—liver cancer	3.37e-05	0.00086	CcSEcCtD
Topotecan—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	3.36e-05	0.00237	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—liver cancer	3.35e-05	0.00236	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HMOX1—liver cancer	3.33e-05	0.00234	CbGpPWpGaD
Topotecan—Dizziness—Doxorubicin—liver cancer	3.29e-05	0.00084	CcSEcCtD
Topotecan—Nausea—Epirubicin—liver cancer	3.19e-05	0.000815	CcSEcCtD
Topotecan—Vomiting—Doxorubicin—liver cancer	3.16e-05	0.000808	CcSEcCtD
Topotecan—Rash—Doxorubicin—liver cancer	3.14e-05	0.000801	CcSEcCtD
Topotecan—Dermatitis—Doxorubicin—liver cancer	3.13e-05	0.0008	CcSEcCtD
Topotecan—Headache—Doxorubicin—liver cancer	3.12e-05	0.000796	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	2.97e-05	0.0021	CbGpPWpGaD
Topotecan—Nausea—Doxorubicin—liver cancer	2.95e-05	0.000755	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—JUN—liver cancer	2.91e-05	0.00205	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC9C1—liver cancer	2.88e-05	0.00203	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—MYO5B—liver cancer	2.88e-05	0.00203	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	2.82e-05	0.00198	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	2.81e-05	0.00198	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—TERT—liver cancer	2.73e-05	0.00193	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC11A2—liver cancer	2.73e-05	0.00192	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	2.72e-05	0.00192	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	2.68e-05	0.00189	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC40A1—liver cancer	2.6e-05	0.00183	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—VEGFA—liver cancer	2.55e-05	0.00179	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ANXA2—liver cancer	2.49e-05	0.00176	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ATP7B—liver cancer	2.49e-05	0.00176	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	2.42e-05	0.0017	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—NR1H4—liver cancer	2.36e-05	0.00166	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	2.33e-05	0.00164	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	2.21e-05	0.00155	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	2.19e-05	0.00154	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—NR1H4—liver cancer	2.15e-05	0.00152	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	2.14e-05	0.00151	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTA3—liver cancer	2.11e-05	0.00149	CbGpPWpGaD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	2.1e-05	0.00148	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	2.08e-05	0.00147	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	2e-05	0.00141	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	1.95e-05	0.00138	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTA4—liver cancer	1.93e-05	0.00136	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	1.93e-05	0.00136	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	1.91e-05	0.00134	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—UGDH—liver cancer	1.89e-05	0.00133	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTA2—liver cancer	1.88e-05	0.00133	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTA1—liver cancer	1.82e-05	0.00128	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—NAT2—liver cancer	1.8e-05	0.00127	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—EPT1—liver cancer	1.78e-05	0.00125	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	1.77e-05	0.00125	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—TAT—liver cancer	1.68e-05	0.00119	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—AKT1—liver cancer	1.62e-05	0.00114	CbGpPWpGaD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	1.61e-05	0.00113	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	1.58e-05	0.00112	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	1.58e-05	0.00111	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	1.51e-05	0.00106	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	1.47e-05	0.00104	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—HPGDS—liver cancer	1.44e-05	0.00101	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	1.41e-05	0.000993	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	1.41e-05	0.00099	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—CASP3—liver cancer	1.41e-05	0.00099	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL2—liver cancer	1.4e-05	0.000989	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	1.38e-05	0.00097	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	1.35e-05	0.00095	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	1.35e-05	0.00095	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	1.27e-05	0.000898	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	1.21e-05	0.000852	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—CYCS—liver cancer	1.2e-05	0.000847	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—VEGFA—liver cancer	1.19e-05	0.00084	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP2E1—liver cancer	1.17e-05	0.000825	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	1.16e-05	0.000814	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CPT1B—liver cancer	1.14e-05	0.000807	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GLUL—liver cancer	1.14e-05	0.000807	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NR1H4—liver cancer	1.1e-05	0.000778	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—TGFB1—liver cancer	1.09e-05	0.000771	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTA3—liver cancer	1.09e-05	0.000765	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GGT1—liver cancer	1.08e-05	0.000758	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	1.06e-05	0.000748	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—HMOX1—liver cancer	1.04e-05	0.000736	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	1.04e-05	0.000733	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—TNF—liver cancer	1.02e-05	0.00072	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—UGDH—liver cancer	1.02e-05	0.00072	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTA4—liver cancer	9.93e-06	0.000699	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	9.84e-06	0.000693	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTA2—liver cancer	9.67e-06	0.000682	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTP1—liver cancer	9.66e-06	0.000681	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—EPT1—liver cancer	9.61e-06	0.000677	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	9.53e-06	0.000671	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTA1—liver cancer	9.33e-06	0.000658	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NAT2—liver cancer	9.23e-06	0.00065	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—TAT—liver cancer	9.11e-06	0.000642	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTM1—liver cancer	8.88e-06	0.000626	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALDOB—liver cancer	8.85e-06	0.000623	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	8.78e-06	0.000619	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	8.76e-06	0.000617	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CRABP1—liver cancer	8.44e-06	0.000595	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—PPARA—liver cancer	8.44e-06	0.000595	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP1A1—liver cancer	8.42e-06	0.000593	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	8.3e-06	0.000585	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	7.72e-06	0.000544	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—HPGDS—liver cancer	7.38e-06	0.00052	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	7.08e-06	0.000499	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	6.93e-06	0.000489	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	6.75e-06	0.000476	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	6.74e-06	0.000475	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	6.68e-06	0.000471	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PSMA4—liver cancer	6.58e-06	0.000463	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PSMD10—liver cancer	6.58e-06	0.000463	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	6.53e-06	0.00046	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	6.5e-06	0.000458	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GOT2—liver cancer	6.4e-06	0.000451	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	6.37e-06	0.000449	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—UGDH—liver cancer	6.29e-06	0.000444	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ALB—liver cancer	6.27e-06	0.000442	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GLUL—liver cancer	6.19e-06	0.000436	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CPT1B—liver cancer	6.19e-06	0.000436	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP2E1—liver cancer	6.01e-06	0.000424	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NR1H4—liver cancer	5.97e-06	0.000421	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—EPT1—liver cancer	5.92e-06	0.000417	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	5.88e-06	0.000415	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTA3—liver cancer	5.87e-06	0.000413	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—RAF1—liver cancer	5.67e-06	0.0004	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	5.65e-06	0.000398	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYCS—liver cancer	5.63e-06	0.000396	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—TAT—liver cancer	5.61e-06	0.000395	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GGT1—liver cancer	5.52e-06	0.000389	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GOT1—liver cancer	5.52e-06	0.000389	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	5.41e-06	0.000381	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	5.4e-06	0.000381	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTA4—liver cancer	5.37e-06	0.000378	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTA2—liver cancer	5.23e-06	0.000369	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTA1—liver cancer	5.05e-06	0.000356	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	5.04e-06	0.000355	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	5e-06	0.000352	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NAT2—liver cancer	4.99e-06	0.000352	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTP1—liver cancer	4.96e-06	0.000349	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—HMOX1—liver cancer	4.89e-06	0.000345	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALDOB—liver cancer	4.78e-06	0.000337	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.6e-06	0.000324	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CRABP1—liver cancer	4.56e-06	0.000322	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	4.56e-06	0.000321	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTM1—liver cancer	4.56e-06	0.000321	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	4.45e-06	0.000313	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP1A1—liver cancer	4.32e-06	0.000304	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—MTHFR—liver cancer	4.03e-06	0.000284	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—HPGDS—liver cancer	3.99e-06	0.000281	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PPARA—liver cancer	3.95e-06	0.000278	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CPT1B—liver cancer	3.81e-06	0.000269	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GLUL—liver cancer	3.81e-06	0.000269	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.75e-06	0.000265	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NR1H4—liver cancer	3.68e-06	0.000259	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTA3—liver cancer	3.62e-06	0.000255	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PSMA4—liver cancer	3.55e-06	0.00025	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PSMD10—liver cancer	3.55e-06	0.00025	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GOT2—liver cancer	3.46e-06	0.000244	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	3.39e-06	0.000239	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CG—liver cancer	3.38e-06	0.000238	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTA4—liver cancer	3.31e-06	0.000233	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PPARG—liver cancer	3.27e-06	0.00023	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP2E1—liver cancer	3.25e-06	0.000229	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTA2—liver cancer	3.22e-06	0.000227	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTA1—liver cancer	3.11e-06	0.000219	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NAT2—liver cancer	3.07e-06	0.000217	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	3.07e-06	0.000216	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYCS—liver cancer	3.04e-06	0.000214	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GOT1—liver cancer	2.99e-06	0.00021	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GGT1—liver cancer	2.99e-06	0.00021	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CD—liver cancer	2.98e-06	0.00021	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALDOB—liver cancer	2.95e-06	0.000208	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALB—liver cancer	2.94e-06	0.000207	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CRABP1—liver cancer	2.81e-06	0.000198	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTP1—liver cancer	2.68e-06	0.000189	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—HMOX1—liver cancer	2.64e-06	0.000186	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CB—liver cancer	2.59e-06	0.000183	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTM1—liver cancer	2.46e-06	0.000174	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—HPGDS—liver cancer	2.46e-06	0.000173	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP1A1—liver cancer	2.34e-06	0.000165	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PSMA4—liver cancer	2.19e-06	0.000154	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PSMD10—liver cancer	2.19e-06	0.000154	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—MTHFR—liver cancer	2.18e-06	0.000153	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PPARA—liver cancer	2.14e-06	0.000151	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GOT2—liver cancer	2.13e-06	0.00015	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP2E1—liver cancer	2e-06	0.000141	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYCS—liver cancer	1.87e-06	0.000132	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GGT1—liver cancer	1.84e-06	0.00013	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GOT1—liver cancer	1.84e-06	0.00013	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CG—liver cancer	1.83e-06	0.000129	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PPARG—liver cancer	1.77e-06	0.000124	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTP1—liver cancer	1.65e-06	0.000116	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—HMOX1—liver cancer	1.63e-06	0.000115	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CD—liver cancer	1.61e-06	0.000113	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALB—liver cancer	1.59e-06	0.000112	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CA—liver cancer	1.58e-06	0.000111	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTM1—liver cancer	1.52e-06	0.000107	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP1A1—liver cancer	1.44e-06	0.000101	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CB—liver cancer	1.4e-06	9.88e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—MTHFR—liver cancer	1.34e-06	9.45e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PPARA—liver cancer	1.32e-06	9.28e-05	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—AKT1—liver cancer	1.29e-06	9.1e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CG—liver cancer	1.13e-06	7.94e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PPARG—liver cancer	1.09e-06	7.67e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CD—liver cancer	9.91e-07	6.98e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALB—liver cancer	9.78e-07	6.89e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CB—liver cancer	8.64e-07	6.09e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CA—liver cancer	8.55e-07	6.02e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—AKT1—liver cancer	6.98e-07	4.92e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CA—liver cancer	5.27e-07	3.71e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—AKT1—liver cancer	4.3e-07	3.03e-05	CbGpPWpGaD
